Galleano I , Harms H , Choudhury K , Khoo K , Delemotte L , Pless SA .

             sodium channel activity

                long QT syndrome 3

	Fig. 1. Phosphorylation of Y1495 destabilizes docking of IFM motif into its receptor site. (A) Schematic of tPTS used to generate Nav1.5 channels that are NM (WT NM) or phosphorylated (WT phY) at the Y1495 position. Amino acids (aa) 1 to 101 of CfaDnaE (orange) are merged to the C terminus of channel fragment corresponding to Nav1.5 aa 1 to 1471 for heterologous expression as the NREC construct. The PSYN sequence corresponds to Nav1.5 aa 1472 to 1502 and is linked to the C-terminal part of CfaDnaE (aa 102 to 137, orange) at its N terminus and the N-terminal part of SspDnaBM86 (aa 1 to 11, yellow) at its C terminus. The corresponding C-terminal part of SspDnaBM86 (aa 12 to 154, yellow) is expressed as a fusion construct at the N terminus of protein fragment C (Nav1.5 aa 1503 to 2016) to form the CREC construct. (B) SSI (Left) and activation (Right) curves of WT NM and WT phY constructs, including example traces and chemical structure of the aa present in position 1495. Data shown as mean ± SD; n = 6 to 9. (C) Contact frequency of Y1495 and IFM particle residues with neighboring residues. Phosphorylation reduces the contact between Y1495 and M1487 of IFM, while it causes the IFM particle to increase contacts with DIII-S6 and DIII–S4-S5 linker. (D) Conformation of IFM particle in its binding site after 200 ns of MD simulation. Phosphorylation of Y1495 moves the loop region of the DIII-DIV linker containing the Q1483 residue outward and the IFM particle closer to the DIII-S6. IFM side chains are highlighted in orange. (E) Free energy profile of IFM unbinding, using the distance between the center of mass (COM) of N1659 in the DIV-S5 helix and F1486 in the IFM particle as a reaction coordinate. WT phY causes a decrease in the binding energy of IFM binding.
	Fig. 2. The Q1476R mutation results in a dramatically shifted SSI. (A) Representative current traces for Q1476R NM (purple) and phY (blue) constructs. (B) SSI (Left) and activation (Right) curves of indicated constructs. (C) Late currents (Upper) and inactivation rates (Lower) for indicated constructs. Data are shown as mean ± SD in B and C; n = 5 to 10; data were compared using unpaired two-tailed Student’s t test; ns (not significant) P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P < 0.0001. Note that the precise measurements of late currents in X. laevis oocytes are hampered by slow-onset, voltage-dependent endogenous currents. Therefore, our late current measurements can only serve as an estimate. (D) Contact frequency of Y1495 and IFM particle with neighboring residues. (E) Conformation of IFM particle in its binding site after 200 ns of MD simulation. Q1476R phY leads to a break in the DIII-S6 helix, leading to the destabilization of IFM binding. IFM side chains are highlighted in orange. (F) Free energy profile of IFM unbinding, using the distance between the COM of N1659 in DIV-S5 helix and F1486 in the IFM particle as a reaction coordinate. Q1476R phY results in a further decrease of binding energy of the IFM particle compared to WT phY and an increased equilibrium distance between F1486 and its docking site due to the break in DIII-S6 induced by the Q1476R mutation.
	Fig. 3. Phosphorylation-induced SSI shift is similar in ΔK1500 and WT. (A) Representative current traces for ΔK1500 NM (light green) and ΔK1500 phY (dark green) constructs. (B) SSI (Left) and activation (Right) curves of indicated constructs. (C) Late currents (Upper) and inactivation rates (Lower) for indicated constructs. Data are shown as mean ± SD in B and C; n = 6 to 10; data were compared using unpaired two-tailed Student’s t test; ns (not significant) P > 0.05, *P ≤ 0.05, ***P ≤ 0.001, and ****P < 0.0001. (D) Contact frequency of Y1495 and IFM particle with neighboring residues. (E) Conformation of the IFM particle in its binding site after 200 ns of MD simulation. I1485 increases its contacts with DIII-S6 residues. IFM side chains highlighted in orange. (F) Free energy profile of IFM unbinding using the distance between the COM of N1659 in the DIV-S5 helix and F1486 in the IFM particle as a reaction coordinate. The binding energy of the IFM particle for the ΔK1500 phY system is similar to that of WT phY.
	Fig. 4. Phosphorylation and disease mutations can affect pharmacological sensitivity of Nav1.5. (A and B) Concentration response curves of WT, Q1476R, and ΔK1500 constructs in response to a 20-Hz pulse train stimulation in presence of AADs quinidine (A) or flecainide (B), respectively (see structures in left panels). P50/P1 values were normalized to range from 0 to 1. (C) IC50 values obtained for quinidine data shown in A. The IC50 is significantly increased by phosphorylation only in WT but not in Q1476R or ΔK1500 constructs. (D) IC50 values obtained for flecainide data shown in B. IC50 values are not significantly altered by phosphorylation in any of the constructs. ns (not significant) P ≥ 0.05 and *P < 0.05. Data shown as mean ± SD; n = 5 to 9. (E) Overlay of flecainide (F) bound to rat Nav1.5 (yellow; PDB code: 6UZ0) and quinidine (Q) bound to human Nav1.5 (orange; PDB code: 6LQA).
	Fig. S1. Schematic overview of the tPTS-based approach to generate semi-synthetic Nav1.5 channels. (A) Split intein A (CfaDnaE; orange) and B (SspDnaB M86; yellow), with N- and C- terminal split intein parts shown separately. Numbers in brackets indicate amino acid numbers of split inteins. (B) Sequence of the synthetic peptide (PSYN) corresponding to amino acids 1472 to 1502 of Nav1.5. Mutated (Q1476R and ΔK1500) or modified (Y1495) sites are highlighted; the IFM motif sequence is underlined. (C) Summary of the approach, with N- and C-terminal Nav1.5 fragments (NREC and CREC) being covalently spliced on both ends of PSYN. Numbers in brackets indicate amino acid numbers in Nav1.5.
	Fig. S2. Western blots of full-length Nav1.5 protein and semi-synthetic channel constructs using antibodies directed against Nav1.5 DI-DII-linker (A) or Nav1.5 C-terminus (B). Top: The respective antibody is schematically shown on the left with its respective epitope (hNav1.5 amino acid numbering) denoted in brackets below it. The detectable constructs (fully spliced protein, splicing educts, splicing side products) are shown in basic topology and their mass is indicated in brackets. Bottom: Western blots of whole-cell lysate from Xenopus laevis oocytes expressing the respective constructs, using a different epitope. Red arrows mark the area around 230 kDa, corresponding to the mass of full length Nav1.5 protein. Lysate from uninjected oocytes and water instead of cell lysate were used as negative controls. Note that the blots also include two constructs with mutated variants of recombinant peptide X (Q1476Rrec, ΔK1500rec).
	Fig. S3. Functional characterization of conventional WT, recombinant reconstituted and semi- synthetic Nav1.5 constructs, as well as conventional single and double mutations. (A) Representative current recordings of Xenopus laevis oocytes injected with the indicated constructs. WT = full length WT Nav1.5; WTREC = NREC + CREC + PREC; WT NM = NREC + CREC + PSYN NM (i.e. containing the Y1495F and the K1479R mutations); WT phY = NREC + CREC + PSYN phY (i.e. containing a phosphonylated tyrosine in position 1495, in addition to the K1479R mutation); Y1495E, full length Nav1.5 Y1495E single mutant; Q1476R+Y1495E, full length Nav1.5 Q1476R+Y1495E double mutant. Note that uninjected oocytes, or those injected with only NREC and CREC (N + C) did not yield currents. (B) and (D) SSI (left) and activation (right) curves of indicated constructs. (C) and (E) Summary of SSI and activation (Act.) parameters of indicated constructs, see Table 1 for details. Data shown as mean ± standard deviation in (B) - (E); n = 6-16, data was compared using unpaired two-tailed student’s t-test, ns (not significant) p > 0.05, * p ≤ 0.05, *** p ≤ 0.001, **** p < 0.0001. Note that the full-length mutant channels were missing the N1472C mutation introduced in the engineered split channels, suggesting that the observed difference in SSI between Q1476R NM and Q1476R phY is likely not an artifact due to the splice-promoting mutation.
	Fig. S4. Recovery from inactivation is accelerated by phosphorylation and the Q1476R patient mutation. (A) Representative current recordings of Xenopus laevis oocytes expressing the indicated semi-synthetic Nav1.5 constructs. Oocytes were subjected to a voltage protocol consisting of two depolarizing voltage pulses to - 20 mV with a recovery interval at - 80 mV of varying length (0.5 ms to 150 ms) in between (see schematic on the right). Only a selection of traces is shown, and some traces are cropped at the beginning for clarity. (B) Recovery of channels is plotted as a single exponential function over increasing recovery intervals. Fractional recovery is calculated as the peak current elicited by the second depolarizing voltage pulse divided by the peak current elicited by the first depolarizing voltage pulse. Recovery interval is the time between the end of the first and the start of the second depolarizing voltage pulse. (C) Tau values of channel recovery, see Table 1 for details. Data shown as mean ± standard deviation; n = 5-7, data was compared using unpaired two-tailed student’s t-test, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p < 0.0001.
	Fig. S5. Phosphorylation and disease mutations can affect pharmacological sensitivity of Nav1.5 towards the anti-arrhythmic drug ranolazine. (A) Concentration response curves of WT, Q1476R and ΔK1500 constructs in response to a 20 Hz pulse train stimulation in presence of the antiarrhythmic drug ranolazine (structure shown in left panel). P50/P1 values were normalized to range from 0 to 1. (B) IC50 values obtained for ranolazine data shown in (A). The IC50 is significantly increased by phosphorylation only in WT and ΔK1500, but not in Q1476R constructs. Data shown as mean ± standard deviation; n = 6-8, data was compared using unpaired two-tailed student’s t-test, ns (not significant) p > 0.05, * p ≤ 0.05, ** p ≤ 0.01.

Ahern, The hitchhiker's guide to the voltage-gated sodium channel galaxy. 2016, Pubmed

Ahern, The hitchhiker's guide to the voltage-gated sodium channel galaxy. 2016, Pubmed
Ahern, Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. 2008, Pubmed , Xenbase
Ahern, Modulation of the cardiac sodium channel NaV1.5 by Fyn, a Src family tyrosine kinase. 2005, Pubmed
Appleby-Tagoe, Highly efficient and more general cis- and trans-splicing inteins through sequential directed evolution. 2011, Pubmed
Armstrong, Inactivation of the sodium channel. II. Gating current experiments. 1977, Pubmed
Attwell, The steady state TTX-sensitive ("window") sodium current in cardiac Purkinje fibres. 1979, Pubmed
Bang, A one-pot total synthesis of crambin. 2004, Pubmed
Baroudi, Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). 2001, Pubmed , Xenbase
Bennett, Molecular mechanism for an inherited cardiac arrhythmia. 1995, Pubmed , Xenbase
Bennett, On the molecular nature of the lidocaine receptor of cardiac Na+ channels. Modification of block by alterations in the alpha-subunit III-IV interdomain. 1995, Pubmed , Xenbase
Berendt, Multisite phosphorylation of voltage-gated sodium channel alpha subunits from rat brain. 2010, Pubmed
Best, Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone φ, ψ and side-chain χ(1) and χ(2) dihedral angles. 2012, Pubmed
Bezanilla, Inactivation of the sodium channel. I. Sodium current experiments. 1977, Pubmed
Bosmans, Palmitoylation influences the function and pharmacology of sodium channels. 2011, Pubmed , Xenbase
Brown, MD-TASK: a software suite for analyzing molecular dynamics trajectories. 2017, Pubmed
Camm, Hopes and disappointments with antiarrhythmic drugs. 2017, Pubmed
Capes, Domain IV voltage-sensor movement is both sufficient and rate limiting for fast inactivation in sodium channels. 2013, Pubmed , Xenbase
Chandra, Multiple effects of KPQ deletion mutation on gating of human cardiac Na+ channels expressed in mammalian cells. 1998, Pubmed
Clairfeuille, Structural basis of α-scorpion toxin action on Nav channels. 2019, Pubmed
Cocco, Torsades de pointes as a manifestation of mexiletine toxicity. 1980, Pubmed
Cormier, Secondary structure of the human cardiac Na+ channel C terminus: evidence for a role of helical structures in modulation of channel inactivation. 2002, Pubmed
Dan, Antiarrhythmic drugs-clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). 2018, Pubmed
Dumaine, Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent. 1999, Pubmed
Echt, Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. 1991, Pubmed
El Refaey, Protein Phosphatase 2A Regulates Cardiac Na+ Channels. 2019, Pubmed
Farinato, Pharmacogenetics of myotonic hNav1.4 sodium channel variants situated near the fast inactivation gate. 2019, Pubmed
Gade, An interaction between the III-IV linker and CTD in NaV1.5 confers regulation of inactivation by CaM and FHF. 2020, Pubmed
Gellens, Primary structure and functional expression of the human cardiac tetrodotoxin-insensitive voltage-dependent sodium channel. 1992, Pubmed , Xenbase
Glaaser, Perturbation of sodium channel structure by an inherited Long QT Syndrome mutation. 2012, Pubmed
Grant, Long QT syndrome, Brugada syndrome, and conduction system disease are linked to a single sodium channel mutation. 2002, Pubmed
Hinard, Annotation of functional impact of voltage-gated sodium channel mutations. 2017, Pubmed
Hoover, Canonical dynamics: Equilibrium phase-space distributions. 1985, Pubmed
Huang, Structure-based assessment of disease-related mutations in human voltage-gated sodium channels. 2017, Pubmed
Iqbal, Phosphorylation of cardiac voltage-gated sodium channel: Potential players with multiple dimensions. 2019, Pubmed
Iqbal, Differential modulation of fast inactivation in cardiac sodium channel splice variants by Fyn tyrosine kinase. 2015, Pubmed
Iqbal, Identification of phosphorylation sites and binding pockets for modulation of NaV 1.5 channel by Fyn tyrosine kinase. 2018, Pubmed
Jiang, Structure of the Cardiac Sodium Channel. 2020, Pubmed
Johnson, Toward quantitative phosphotyrosine profiling in vivo. 2012, Pubmed
Kapplinger, Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. 2009, Pubmed
Khoo, Chemical modification of proteins by insertion of synthetic peptides using tandem protein trans-splicing. 2020, Pubmed , Xenbase
Klauda, Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. 2010, Pubmed
Kroncke, SCN5A (NaV1.5) Variant Functional Perturbation and Clinical Presentation: Variants of a Certain Significance. 2018, Pubmed
Lee, CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. 2016, Pubmed
Li, Structural Basis for Pore Blockade of the Human Cardiac Sodium Channel Nav 1.5 by the Antiarrhythmic Drug Quinidine*. 2021, Pubmed
Li, Structure of human Nav1.5 reveals the fast inactivation-related segments as a mutational hotspot for the long QT syndrome. 2021, Pubmed
Li, Convergent regulation of sodium channels by protein kinase C and cAMP-dependent protein kinase. 1993, Pubmed
Lorenzini, Proteomic and functional mapping of cardiac NaV1.5 channel phosphorylation sites. 2021, Pubmed
Lundby, In vivo phosphoproteomics analysis reveals the cardiac targets of β-adrenergic receptor signaling. 2013, Pubmed
Marionneau, Regulation of the cardiac Na+ channel NaV1.5 by post-translational modifications. 2015, Pubmed
Melillo, Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. 1996, Pubmed
Moreau, Sodium overload due to a persistent current that attenuates the arrhythmogenic potential of a novel LQT3 mutation. 2013, Pubmed
Motoike, The Na+ channel inactivation gate is a molecular complex: a novel role of the COOH-terminal domain. 2004, Pubmed
Noble, Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium-calcium overload. 2006, Pubmed
Patton, Amino acid residues required for fast Na(+)-channel inactivation: charge neutralizations and deletions in the III-IV linker. 1992, Pubmed
Pedersen, Site-Specific Phosphorylation of PSD-95 PDZ Domains Reveals Fine-Tuned Regulation of Protein-Protein Interactions. 2017, Pubmed
Ping, Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits. 1999, Pubmed
Rivolta, Inherited Brugada and long QT-3 syndrome mutations of a single residue of the cardiac sodium channel confer distinct channel and clinical phenotypes. 2001, Pubmed
Sarhan, Crystallographic basis for calcium regulation of sodium channels. 2012, Pubmed
Schwartz, Inherited cardiac arrhythmias. 2020, Pubmed
Schwartz, Long-QT syndrome: from genetics to management. 2012, Pubmed
Shen, Structure of a eukaryotic voltage-gated sodium channel at near-atomic resolution. 2017, Pubmed
Shi, Development of a tandem protein trans-splicing system based on native and engineered split inteins. 2005, Pubmed
Stevens, Design of a Split Intein with Exceptional Protein Splicing Activity. 2016, Pubmed
Takahashi, Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel. 2001, Pubmed
Tateyama, Structural effects of an LQT-3 mutation on heart Na+ channel gating. 2004, Pubmed
Thornhill, Biosynthesis of electroplax sodium channels in Electrophorus electrocytes and Xenopus oocytes. 1987, Pubmed , Xenbase
Tsai, Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. 2015, Pubmed
Vikram, Sirtuin 1 regulates cardiac electrical activity by deacetylating the cardiac sodium channel. 2017, Pubmed
Viswanathan, Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes. 2001, Pubmed
Wang, Inhibition of fast sodium current in rabbit ventricular myocytes by protein tyrosine kinase inhibitors. 2003, Pubmed
Watson, Mosquito-Derived Anophelin Sulfoproteins Are Potent Antithrombotics. 2018, Pubmed
West, A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation. 1992, Pubmed , Xenbase
Wu, CHARMM-GUI Membrane Builder toward realistic biological membrane simulations. 2014, Pubmed
Yamaura, STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning. 2003, Pubmed
Zhu, Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation. 2019, Pubmed , Xenbase